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Abstract
Background
In 2011, a unique Q fever vaccination campaign targeted people at risk for chronic Q fever
in the southeast of the Netherlands. General practitioners referred patients with defined car-
diovascular risk-conditions (age >15 years). Prevalence rates of those risk-conditions were
lacking, standing in the way of adequate planning and coverage estimation. We aimed to
obtain prevalence rates retrospectively in order to estimate coverage of the Q fever vaccina-
tion campaign.
Methods
With broad search terms for these predefined risk-conditions, we extracted patient-records
from a large longitudinal general-practice research-database in the Netherlands (IPCI-data-
base). After validation of these records, obtained prevalence rates (stratified for age and
sex) extrapolated to the Q fever high-incidence area population, gave an approximation of
the size of the targeted patient-group. Coverage calculation addressed people actually
screened by a pre-vaccination Q fever skin test and serology (coverage) and patients re-
ferred by their general practitioners (adjusted-coverage) in the 2011 campaign.
Results
Our prevalence estimate of any risk-condition was 3.1% (lower-upper limits 2.9-3.3%). For
heart valve defects, aorta aneurysm/prosthesis, congenital anomalies and endocarditis,
prevalence was 2.4%, 0.6%, 0.4% and 0.1%, respectively. Estimated number of eligible
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people in the Q fever high-incidence area was 11,724 (10,965-12,532). With 1330 people
screened for vaccination, coverage of the vaccination campaign was 11%. For referred peo-
ple, the adjusted coverage was 18%. Coverage was lowest among the very-old and highest
for people aged 50–70 years.
Conclusion
The estimated coverage of the vaccination campaign was limited. This should be inter-
preted in the light of the complexity of this target-group with much co-morbidity, and of the
vaccine that required invasive pre-vaccination screening. Calculation of prevalence rates of
risk-conditions based on the IPCI-database was feasible. This procedure proved an efficient
tool for future use, when prevalence estimates for policy, implementation or surveillance of
subgroup-vaccination or other health-care interventions are needed.
Introduction
In 2007, a large human Q fever outbreak started in the southeast of the Netherlands, caused by
exposure to goat-farms infected by Coxiella burnetii [1]. Subsequently, the annual number of
reported human Q fever cases reached a peak of 2354 in 2009. The increase of acute Q fever re-
ports was followed by increasing numbers of chronic Q fever patients [2]. Chronic Q fever is a
severe outcome of C. burnetii infection, often presenting itself as endocarditis or vascular infec-
tion, and needs long-term antibiotic treatment and often surgical intervention [3]. Several car-
diovascular risk-conditions for chronic Q fever have been identified [4,5], and the Health
Council (HC) of the Netherlands advised vaccination of people aged 15 years and over, with
these specific risk-conditions in July 2010 [6]. This measure was an individual patient-oriented
intervention and not a population-targeted campaign. The sole available vaccine, only regis-
tered in Australia where it is used to vaccinate people at occupational risk [7,8], requires pre-
vaccination screening [9,10], and therefore complicated logistics [11]. The Ministry of Health
chose a centralized approach, coordinated by the National Institute for Public Health and Envi-
ronment. Efforts to reach the target population concentrated on high-incidence areas [Fig 1]
and relied on general practitioners (GPs), and to a lesser extent to hospital specialists, for pa-
tient referrals. Intake, screening and subsequent vaccination was organized at the municipal
health clinic in the central high-incidence area. The vaccination campaign included intensified
safety surveillance [12], immunological pre-vaccination screening and immunological follow-
up [11,13].
In their advice, the HC did not attempt to quantify the size of the risk-group eligible for vac-
cination and no concise prevalence data of the risk-conditions were available according to car-
diologists. In the planning phase of the vaccination campaign, which should start before the
approaching lambing season, it was estimated that 100–300 people would respond to the invi-
tation for vaccination within the target population, and 1000 was taken as upper limit budget
wise. The much larger than expected number of referred people (2741) overloaded the system
and made implementation of the campaign difficult, forcing an up-scaling of staff [11]. In the
end, 1786 eligible people underwent screening tests between January and April 2011.
The lack of prevalence data of the risk-conditions not only precluded determination of the
size of the target population, but also of the coverage of the vaccination campaign. In order to es-
timate coverage retrospectively, we needed to obtain prevalence estimates of the risk-conditions
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for chronic Q fever in the high-incidence area. To this end, we extracted data on the specific
risk-conditions from the Integrated Primary Care Information (IPCI)-database, a large longitu-
dinal population-based general practice research database in the Netherlands. Here we describe
the procedure we followed to arrive at an estimate of the coverage of the Q fever vaccination
campaign in the Netherlands 2011 [14].
Materials and Methods
IPCI-database
The IPCI-database is a longitudinal general practice research database held by Erasmus Uni-
versity Medical Center, Rotterdam. With data collection since 1996, this electronic dynamic
database presently contains 1.1 million patient-records from 437 general practices in the Neth-
erlands [15–17]. It holds comprehensive information on medical history and referrals. Includ-
ed are signs and symptoms, diagnoses, International Classification of Primary Care (ICPC)-
codes, laboratory test results, surgical procedures, medication and hospitalizations. The free
text fields of the records contain summaries or full discharge letters from hospital specialists.
Hard copies of letters are available upon request. The patient population is representative of
the Dutch population, with some underrepresentation of elderly people who have moved to
nursing homes however [17]. Patient-records are anonymous for researchers. IPCI complies
with European Union guidelines on secondary use of healthcare data for medical research. The
IPCI-database is valid for pharmaco-epidemiological research and has been used in more than
100 peer-reviewed publications. The Supervisory Board of the IPCI-database (project number
Fig 1. Municipalities with their incidence of Q fever in 2009–2010.Q fever high-incidence area outlined in
black (11).
doi:10.1371/journal.pone.0123570.g001
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11/2012) approved the use of IPCI-data for the current prevalence estimation. Approval by the
ethics committee was not necessary for this retrospective study because only anonymous data
have been used.
Study population
The source population comprised all patients 15 years and older who were registered with one
of the GP-practices and actively in follow-up with the GP on January 1st 2011 [6]. Due to re-
source limitations regarding the necessary manual validation of extracted patient-records, we
sampled 5% of this source population as study population. We compared the characteristics of
the full source population and those of the 5% random sample for consistency in pattern of
non-validated potential cases.
Risk-conditions and search criteria
Four risk-conditions were defined, based on the HC-advice of eligibility for Q fever vaccination
[6]. Relevant search terms were entered in a script (syntax) with which the database was
searched in diagnostic code sections and free text fields [Table 1]. Physicians (PEVdB and TS)
reviewed the electronic medical records of all potential cases in order to assess validity and
label the diagnostic certainty. They entered the level of diagnostic certainty (definite-probable-
possible case or no case) in a validation tool with date of first diagnosis or of rejection. Cases
Table 1. Cardiovascular risk-conditions for chronic Q fever with ICPC-codes, search terms and diag-
nostic certainty levels.
Risk-conditions, ICPC-codesa, search terms and diagnostic certainty levels for IPCI-databaseb
extraction
Risk-conditions and
ICPC-codesc
1- valvular cardiac disease or prosthesis (symptomless mitral valve
prolapse excluded) (K83)
2- aortic aneurysm of prosthesis/stent (K99)
3- congenital cardiac anomalies (except spontaneous closure of VSD/ASD/
OBD or surgical closure without artiﬁcial material and no residual defect),
inclusive of coarctatio aortae (K73)
4- history of endocarditis or rheumatic cardiac disease (K71)
Search terms in free text a- valv*, aort*, aneury*, congenit*, viti*, prosth*, vsd/asd, obd, mitra*,
tricusp*, stenos*, insuff*, endocardi* and the Dutch equivalents,
etcetera’s
b- proper names of different (congenital) syndromes like Eisenmenger,
Fallot, Epstein, Ivemark, Botalli, etcetera’s. All these search terms
included also possible spelling errors
Level of diagnostic
certainty
1- certain; with discharge letter of specialist or speciﬁc diagnostic laboratory
outcome, or repetitive entries with description and speciﬁc treatment
2- probable; with only descriptions entered by the general practitioner, with
the correct ICPC-codes
3- possible; with only (recurrent) ICPC-code, without description of
condition, or minimal defects with uncertain consequences
4- rejected; if condition could be regarded as variant of normal, minimal
defects without any consequences, or falling within exclusion criteria, as
well as conditions excluded by specialist examination, or conditions in
family members
a ICPC-codes, International Classiﬁcation of Primary Care codes
b IPCI-database, Integrated Primary Care Information database
c Qualifying patients were eligible for Q fever vaccination in the campaign of 2011
doi:10.1371/journal.pone.0123570.t001
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could have multiple risk-conditions. We did not subdivide the cases according to severity or
type of defect within the specific risk-conditions, since this was not the scope of our study. A
random sample of 100 records was crosschecked by independent review (AMV). These records
and all cases with the lowest level of diagnostic certainty (possible) were thereafter checked for
consistency, held against strict inclusion criteria, and coded following consensus (PEVdB
and TS).
Population of the Q fever high-incidence area and the Q fever
vaccination campaign
The population distribution of the Q fever high-incidence area as of January 1st 2011was re-
trieved from demographic data from the electronic databank Statline (Statistics Netherlands,
http://statline.cbs.nl/Statweb). Information on actually referred and screened people in the Q
fever vaccination campaign was obtained from the case report forms of the Q fever vaccination
campaign as described previously [12]. Risk-conditions of referred people came from GPs and
from the potential vaccinees themselves. Postal codes identified referred people living in the
high-incidence area. Of 2741 potential vaccinees, 955 were excluded for various reasons [11].
The remaining 1786 people—of which 1330 from the high-incidence area—underwent pre-
vaccination screening with skin test and serology, and—if negative—were subsequently vacci-
nated. Logistics and safety surveillance of the Q fever vaccination campaign have been de-
scribed elsewhere [11,12].
Data analysis
After validation and review of extracted patient-records from the IPCI-sample, stratified num-
bers on the four defined risk-conditions according to 10 years’ age groups and sex, were used
to determine prevalence (N/10,000), with 95% Confidence Intervals (95%CI). We did so both
for all confirmed cases and for cases with definite and probable diagnostic certainty only, with
lower and upper limits.
The prevalence estimates for cases with definite and probable diagnostic certainty, stratified
for age group and sex, served as input for the high-incidence area population, to approximate
the number of people eligible for Q fever vaccination in this region. With this, the coverage of
the vaccination campaign was determined with minimum and maximum estimates based on
the 95% CI of the IPCI-sample data. Fig 2 presents a diagram with the calculation steps. Open-
Epi and Excel were used for calculations and graphs.
Results
The IPCI-database per January 1st 2011 contained 651,276 people aged 15 years and over. The
5% random sample as study population had comparable age and sex distribution. The relative
age distribution of the populations of the IPCI-sample and of the high-incidence area (as ob-
tained from CBS) shows that they were similar (with equal median age), though the latter had
slightly less people in the age group of 20–30 years and more in the 50–60 year olds [Fig 3].
The IPCI-study population included 32,571 people [Table 2]. We identified 1966 patient-
records (6%) with one or more ICPC-codes and/or search terms for chronic Q fever risk-condi-
tions [Table 1], women (52.7%) slightly outnumbering men (47.3%). After review and valida-
tion, we rejected 948 extracted patients in all (viz. hits for family members with a risk-
condition, or medical investigation ruling out a specified risk-condition, or non-qualifying di-
agnoses). This left 1018 (52%) cases with one or more confirmed chronic Q fever risk-condi-
tions. Of these, 177 (17%) had possible diagnostic certainty and 841 definite or probable
diagnostic certainty [Fig 4].
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Fig 2. Flow diagram of calculations leading to coverage estimates. For calculations, prevalence of risk-
conditions with definite and probable diagnostic certainty from IPCI-study population has been used, overall
and for subgroups.
doi:10.1371/journal.pone.0123570.g002
Fig 3. Population distribution of IPCI-database and of Q fever high-incidence area. (A) population
pyramids for IPCI-database (dark colours) and for Q fever high-incidence (HI)- area (light colours), according
to sex. (B) Relative age frequencies for IPCI-source population (open squares), IPCI-study population
(triangles) and for Q fever HI-area (open circles).
doi:10.1371/journal.pone.0123570.g003
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The majority of confirmed cases from the IPCI-study population (925/1,018; 91%) had only
one defined risk-condition and 9.1% had multiple risk-conditions, mostly double and only
three triple (male 11.5% and female 7.0%). Valvular disease was most prevalent (778; 148 possi-
ble), followed by aortic aneurysm or prosthesis (183; 10 possible), congenital cardiac anomalies
(116; 28 possible) and endocarditis (37; 15 possible) [Table 2 and Fig 4].
Table 2. Risk-conditions for chronic Q fever in the IPCI-study population, according to age groups and sex.
IPCI-population, risk-conditions, prevalence rates and age groups
IPCI-study population (number)
Age group 15–20 20–30 30–40 40–50 50–60 60–70 70–80 80–90 >90 yrs all
All 2158 4708 5001 6224 5509 4454 2837 1447 233 32571
male 1093 2354 2400 3047 2728 2138 1300 579 72 15711
female 1065 2354 2601 3177 2781 2316 1537 868 161 16860
male% 51% 50% 48% 49% 50% 48% 46% 40% 31% 48%
Risk-conditions (number)a
Age group 15–20 20–30 30–40 40–50 50–60 60–70 70–80 80–90 >90 yrs all
Heart valve defect 3 9 14 54 67 166 225 199 41 778
Aortic aneurysm/prosthesis 1 2 0 7 19 38 63 49 4 183
Congenital heart anomaly 15 24 17 24 14 14 3 5 0 116
Endocarditis 0 1 3 4 7 12 6 4 0 37
Any risk condition 16 31 30 82 94 212 269 241 43 1018
male 6 16 11 34 44 111 142 110 13 487
female 10 15 19 48 50 101 127 131 30 531
male% 38% 52% 37% 41% 47% 52% 53% 46% 30% 48%
Prevalence of risk-conditions (/10,000)a
Age group 15–20 20–30 30–40 40–50 50–60 60–70 70–80 80–90 >90 yrs all
Heart valve defect 14 19 28 87 122 373 793 1375 1760 239
male 9 21 21 66 106 379 815 1347 1667 214
female 19 17 35 107 137 367 774 1394 1801 262
Aortic aneurysm/prosthesis 5 4 0 11 34 85 222 339 172 56
male 0 8 0 13 51 131 385 674 417 89
female 9 0 0 9 18 43 85 115 62 26
Congenital heart anomaly 70 51 34 39 25 31 11 35 0 36
male 55 51 29 39 22 33 15 17 0 34
female 85 51 38 38 29 30 7 46 0 37
Endocarditis 0 2 6 6 13 27 21 28 0 11
male 0 4 0 3 15 28 23 17 0 10
female 0 0 12 9 11 26 20 35 0 12
Any risk-condition 74 66 60 132 171 476 948 1666 1845 313
lower limit 46 46 42 106 140 417 846 1482 1400 294
upper limit 120 93 86 163 208 543 1062 1866 2393 332
male 55 68 46 112 161 519 1092 1900 1806 310
female 94 64 73 151 180 436 826 1509 1863 315
Distribution of the full IPCI-study population; number of conﬁrmed risk-conditions in the IPCI-study population; prevalence estimates of risk-conditions per
10,000 according to sex, as calculated from the IPCI-study population, with lower and upper limits.
a The scoring of risk-conditions as shown here, applies to all conﬁrmed cases, including possible and probable/deﬁnite diagnostic certainty.
doi:10.1371/journal.pone.0123570.t002
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The relative frequencies of the four risk-conditions in the IPCI-study population were simi-
lar to those in the screened people of the Q fever campaign and the screened people from the
high-incidence area [Fig 5A]. However, the screened people were younger than the confirmed
Fig 4. Flow diagram of results of IPCI-database extraction and validation. Sex distribution (male %)
included for each step.
doi:10.1371/journal.pone.0123570.g004
Fig 5. Relative frequencies of risk-conditions for chronic Q fever and sex distribution in the different
populations. (A) Comparison between all screened people of the Q fever (QF)-vaccination campaign,
screened people from the high-incidence (HI)-area, and cases from the IPCI-study population. (B) Sex
distribution for different risk-conditions in screened people from QF-HI-area and cases from IPCI-study
population. The IPCI-study population includes cases with definite and probable diagnostic certainty.
doi:10.1371/journal.pone.0123570.g005
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cases with definite and probable diagnostic certainty from the IPCI-study population. Median
(interquartile range) ages were 67 (57–74) and 72 (61–81) years for screened people and IPCI-
cases, respectively. IPCI-cases with possible diagnostic certainty were younger and had a higher
proportion of women (58% versus 51%). The proportion of men was higher in the referred and
screened people of the Q fever vaccination campaign from the high-incidence area (61%) than
in the IPCI-study population cases (48%), for all risk-conditions except for congenital heart
anomalies [Figs 4 and 5B].
The overall prevalence of any risk-condition in the IPCI-study population was 313 per
10,000 people, increasing with age [Fig 6]. Only for congenital anomalies, prevalence was high-
est in the youngest age group. Men and women showed almost equal overall prevalence rates
of 310 and 315 per 10,000, respectively [Table 2]. These calculated prevalence rates for the dif-
ferent risk-conditions are within data ranges presented in literature [Table 3].
To get an impression of the proportion of eligible people who were reached in the Q fever
vaccination campaign (coverage), one should first calculate prevalence estimates for validated
IPCI-cases with definite and probable diagnostic certainty [Fig 2]. These prevalence rates were
stratified for age group and sex, with an overall rate of 258/10,000 [S1 Table]. Extrapolation of
these rates to the population of the Q fever-high-incidence area, led to an estimated number of
targeted people of 11,724 (10,965–12,532) [S2 Table]. If people from municipalities bordering
the high-incidence area were included in this calculation, the target group would number at
least 15,000 people.
Overall, only 1330 of this target group from the high incidence area were screened for vacci-
nation [Table 4], which resulted in coverage of 11% (1330/11,724) with narrow lower and
upper limits of 11–12%. For men and women these coverage rates were 14% (13%-15%) and
Fig 6. Age distribution of the defined risk conditions for chronic Q fever. Prevalence rates (per 10,000)
are estimated from the IPCI-database, per January 1st 2011.
doi:10.1371/journal.pone.0123570.g006
Table 3. Prevalence rates for separate cardiovascular risk conditions and comparison with literature.
Risk-conditions Prevalence/
100
Overall Range for age
groups
Lower- upper
limits
Male;
peak
Female;
peak
Range in
literature
Lit ref
#
Heart valve defect 2.39 0.1–17.6 2.23–2.56 2.14; 16.67 2.62; 18.01 0.2–13.0 28–33
Aortic aneurysm/prosthesis 0.56 <0.05–3.0 0.49–0.65 0.89; 6.74 0,26; 3.39 up to 8.9 33–38
Congenital heart anomaly 0.36 <0.1–0.7 0.30–0.43 0.34; 0.55 0.37; 0.85 0.4–0.8 39–44
Endocarditis 0.11 0–0.28 0.08–0.16 0.10; 0.28 0.12; 0.35 0.12 45–46
Any risk condition 3.1 0.6–18.5 2-94-3.32 3.10; 19.00 3.15; 18.63 - -
Prevalence per 100 people with lower and upper limits and range over the age groups and sex distribution with peak prevalence.
doi:10.1371/journal.pone.0123570.t003
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9% (8%-10%), respectively. For the larger group of referred people from the high-incidence
area, an adjusted coverage rate of 18% (limits 16%-18%) was calculated. Coverage was lowest
in the oldest age groups, with 5% and 1% for the 80–90 year olds and 90 years and older, re-
spectively. The highest coverage was in the much larger groups of the 50–60 and 60–70 year
olds, with 19% and 16% respectively (upper limits of 23% and 19%). Based on the referred peo-
ple in these latter age groups, this would result in an adjusted coverage of approximately 30%
and 24% (upper limits 34% and 29%) [Table 5].
Discussion
This study aimed to evaluate the quantitative performance of the Q fever vaccination campaign
in 2011, which targeted people at risk for chronic Q fever. Prevalence data for the defined risk-
conditions were not available at the time and no disease registers exist in the Netherlands. In
this retrospective cohort study, we identified the number of people with those predefined risk-
conditions for chronic Q fever in a random sample of a population-based database, from
which we calculated stratified prevalence estimates. By extrapolation of these prevalence data
to the population of the high-incidence area of the Q fever epidemic, we arrived at an approxi-
mation of about 12,000 people with a definite or probable cardiovascular condition
Table 4. Risk-conditions for chronic Q fever of screened patients in the vaccination campaign in 2011.
Risk-conditions and age groups 15–20 20–30 30–40 40–50 50–60 60–70 70–80 80–90 >90 yrs all
Heart valve defect 14 14 20 62 145 305 280 85 4 929
Aortic aneurysm/prosthesis 0 1 1 4 33 101 122 32 0 294
Congenital heart anomaly 17 14 21 34 11 8 4 0 0 109
Endocarditis 3 0 3 4 9 10 7 1 0 37
Any risk-condition 30 30 40 97 192 417 409 111 4 1330
male 15 19 20 44 111 283 257 64 2 815
female 15 11 20 53 81 134 152 47 2 515
Only patients included from the high-incidence area, stratiﬁed according to age groups and sex.
doi:10.1371/journal.pone.0123570.t004
Table 5. Coverage of Q fever vaccination in the high-incidence area, for risk-conditions separately and combined.
Coverage and age
groups
15–
20
20–
30
30–
40
40–
50
50–
60
60–
70
70–
80
80–
90
>90yrs all lower
limit
upper
limit
(all
adjusted)
Heart valve defect 30% 14% 13% 12% 21% 16% 11% 4% 1% 11% 10% 11% (17%)
Aortic aneurysm /
prosthesis
0% 8% 0% 5% 12% 19% 15% 6% 0% 12% 11% 14% (21%)
Congenital heart anomaly 8% 5% 14% 13% 10% 5% 10% 0% 0% 9% 7% 11% (16%)
Endocarditis 10% 0% 11% 28% 13% 10% 10% 8% 0% 12% 8% 18% (27%)
Any risk condition 14% 9% 13% 12% 19% 16% 13% 5% 1% 11% 11% 12% (18%)
lower limit 8% 6% 9% 9% 15% 14% 11% 4% 1% - - - -
upper limit 24% 13% 20% 15% 23% 19% 14% 5% 1% - - - -
male 19% 10% 17% 12% 21% 20% 15% 6% 2% 14% 13% 15% (23%)
female 11% 7% 11% 12% 16% 12% 10% 4% 1% 9% 8% 10% (15%)
Coverage based on screened patients in the Q fever vaccination campaign from the high-incidence area and stratiﬁed for age groups and sex. Lower and
upper limits based on 95%CI of the prevalence estimates. Adjusted coverage for all age groups combined calculated with the number of referred patients
from the high-incidence area in the Q fever vaccination campaign.
doi:10.1371/journal.pone.0123570.t005
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predisposing to chronic Q fever for this particular area. Using the recorded number of people
actually screened for Q fever vaccination from this area, we estimated the overall coverage to
be 11% (upper limit 12%). The adjusted coverage estimate, based on the larger group of re-
ferred people, was 18%.
There are several possible explanations for this limited coverage. First, the centralized ap-
proach, with only one location and limited dates for screening and vaccination may have posed
a barrier for eligible people. Moreover, potential vaccinees had to travel twice because of the re-
quired and invasive pre-vaccination skin test and serology. As the vaccine was unregistered, in-
formation leaflets and letters were sent to cardiologists and GPs and to potential vaccinees, in
which uncertainties were described explicitly; this may have influenced their willingness to
refer or to be vaccinated. Furthermore, potential vaccinees needed to sign multiple consent
forms, which may have been another barrier to refer or to consent. The necessity to fill in sever-
al diaries to record experienced adverse events and the intensified safety surveillance with fol-
low-up by telephone may have put off quite some referred people. Reasons for secondary
withdrawal were, among others, too far- unsafe/perceived risk benefit misbalance- intercurrent
illness- feeling to be a guinea pig- difficult/impossible day/date- lack of transport- etcetera.
Some potential vaccinees could not walk, were bedridden, or felt they were not at risk because
they hardly ever left their home. Some other people were excluded because one felt they were
unable to comply with the requirements of informed consent and follow-up. Hence the low
coverage in the oldest age groups. Moreover, when the vaccination campaign finally took off,
the outbreak was already in decline due to the effects of consecutive veterinary interventions in
the year before; the urgency of vaccination was felt less, not only by referring GPs and their pa-
tients but also by the coordination team of the campaign and its implementers. In December
2010, HC decided not to include (new) occupational risk groups because risk of infection had
sufficiently decreased [18]. This led to the decision not to extend the relative short intake peri-
od for the Q fever vaccination campaign. In contrast with population based campaigns or pro-
grammes, no repeated public education and information was launched. To avoid the so-called
“worried well” phenomenon, the public were not addressed directly. The short time span be-
tween informing the public and professionals, recruitment of potential vaccinees and the
screening and vaccination period, posed an obstacle to timely referral and intake. As reported
[11], GPs had varying degrees of difficulty to identify eligible patients from the files depending
on their file system specifications and codes. Lastly, the lack of prevalence data may have nega-
tively influenced coverage in an indirect way, as inadequate logistics for coping with a much
larger than expected number of indicated patients may have put off some patients, because
convenient appointments could not easily be made.
For coverage estimation, we left out all cases labelled as possible from the IPCI-study popu-
lation because many were early cases and of the mildest severity, without full clinical work up.
GPs might not interpret most of these patients to be at high-risk for chronic Q fever; neither
would these people think so themselves. We calculated coverage for people included in pre-
vaccination screening, as this group was effectively enrolled, instead of for people referred as
the larger group that was potentially reached. For this latter group, adjusted coverage would be
approximately 50% higher. Coverage estimation was based on the Q fever high-incidence area
(75% of all screened people), for which we had retrieved background population numbers.
The coverage estimates varied somewhat among risk-conditions and age groups. The low
coverage in the two oldest age decades is not surprising in the light of the obstacles and criteria
mentioned before. The highest coverage was in the (largest) middle age groups, with 19% and
16% for 50–60 and 60–70 years old, respectively. Men had higher coverage rates than women.
In the light of the higher Q fever risk in these specific age groups and in men [19], this is a posi-
tive finding. These risk factors were included in the HC-advice [6] and in information letters to
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GPs, possibly leading to increased referral. Women were underrepresented in referral and
screening for Q fever-vaccination. An explanation might be that they have milder (asymptom-
atic) cardiovascular defects or were less receptive to be referred for vaccination [20].
In contrast to the well-incorporated Dutch universal childhood vaccination programme
(over 95% coverage, except for HPV due to concerns about safety and necessity) [21][, coverage
for other (adult) risk-group vaccination is often disappointingly low, even after official and re-
peated recommendations [22–26]. The annual influenza vaccination programme sticks out
comparatively positively but for the hepatitis B vaccination for men having sex with men the
estimated annual coverage of only 1% [27]. Such risk-group targeted vaccinations are also hard
to monitor, especially if executed in the private sector without disease databases and vaccina-
tion registers [28].
The calculated prevalence estimates for the four risk-conditions showed that overall, 3.1%
of the population of 15 years and older had one or more of the defined conditions, increasing
with age and similar for men and women. One might think that prevalence estimates could
have been retrieved from literature before the start of the vaccination campaign. This could
have prevented some of the logistic pressures because of the unexpected large influx of refer-
rals. Data on prevalence of valvular defects [29–34], aortic aneurysms [35–39], congenital
heart anomalies [40–45], and endocarditis [46,47] can indeed be found in literature [Table 3].
Some publications are quite recent, however, and very few are from the Netherlands [37].
There is no reason though, to expect substantial differences in prevalence rates between devel-
oped countries, but some racial or ethnic differences have been described [48], as well as
changes over time, better therapeutic procedures and higher life expectancy [43].
The prevalence estimates in this study are the first available in the Netherlands. Heart valve
defects, as the most common risk-condition presented in 2.4%, with peak prevalence of 17.6%
in the older age groups. Aortic aneurysm/prosthesis occurred in 0.6%, with peak prevalence of
3%. Congenital cardiovascular anomalies were a rather small group in the IPCI-study popula-
tion as well as in the Q fever vaccination campaign and were comparatively overrepresented in
the youngest age group. This may be because patients with the more severe defects may not
have survived, or recent severe degenerative or acquired symptomatic changes may have over-
shadowed the primary condition. Prevalence estimates for all risk-conditions seem to be well
in line with the rather scarce reports in literature.
Observed prevalence rates indicate that a very large group of people in the population is
at substantial risk of Q fever complications. Not only those living in the high-incidence area
at the time, but also those living in the proximity of infected farms in other areas. Of note,
environmental Coxiella burnetii has the potential to spread over great distances [49,50]. Sero-
prevalence studies conducted in 2009–2011 have found a large proportion (>10%) of people
infected by C. burnetii and illustrates the magnitude of the Dutch Q fever outbreak [51]. For
the future, containing Q fever is of great importance, and relaxation of veterinary measures, i.e.
mandatory vaccination and tank milk surveillance for Q fever at goat-farms, could pose a great
hazard for this prevalent risk group. Therefore, veterinary measures containing Q fever need to
be continued.
A difficulty for this study was that the risk-conditions searched for in the IPCI- database re-
quired long string search terms in addition to ICPC-codes and manual validation. This was
necessary because much information on these risk-conditions was captured in unstructured
text in GP information systems. Medical expertise was necessary to validate the patients, be-
cause patient-records had to be assessed in medical perspective. With searches based on ICPC-
codes alone, a large proportion of qualifying patients would have been missed. Patients with
only an ICPC-code for risk-condition, qualified for the lowest level of diagnostic certainty (pos-
sible) at most, because free text substantiation was missing. In addition, some patients with an
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incorrect code would have been included without the free text validation. Some miscoding may
occur after several consecutive changes in the coding system and because of misunderstanding
by the coding-assistant. For instance, several times, the rheumatic fever code-in Dutch acute
rheuma(tic disease)- was mistakenly chosen in cases of acute presentation of polyarthritis rheu-
matica. Perusing the free text entries, this could be sorted out in the majority of cases. We may
have missed less obvious misconceptions, however. In addition, not all risk-conditions or tar-
geted interventions had codes that were specific enough.
As the Q fever vaccination campaign was not designed as a study, indications for referral,
especially in people with multiple risk-conditions, may not have been completely reported. On
the other hand, checking of people’s eligibility was strict and all underlying risk-conditions
were critically reviewed, before acceptation for pre-vaccination screening. Even so, only a small
percentage (2.9%) of referred people was rejected because proper indication lacked or because
of young age.
A strength of this study is that the IPCI-study population—which we used to calculate prev-
alence estimates of the risk-conditions—was representative of the Dutch population. The exis-
tence of population registers enabled us to extrapolate these prevalence estimates to the Q fever
high-incidence area. The consistency of the yield with prevalence data available from literature
and the similar relative frequencies for the respective risk-conditions in the Q fever vaccination
campaign and the IPCI-study population inspire confidence. We assume high sensitivity of our
search strategy with the broad search terms we chose (including spelling errors), while we did
not come across other terms or synonyms for the conditions we were after in the free text of
the validated records. In this perspective, the relative high proportion of rejections after valida-
tion was reassuring. We increased specificity through this individual validation of the full ex-
tracted patient group and subsequent review of all borderline cases with subsequent inclusion
or rejection. Moreover, the called for risk-conditions had a relative high frequency in the gener-
al population resulting in precise estimates with small 95% confidence intervals.
In conclusion, the estimated coverage of the Q fever vaccination campaign of 11–18% was
limited, but is understandable if all obstacles are taken into account. The IPCI-database extrac-
tion for determination of risk-condition prevalence rates turned out to be a feasible procedure
within a limited time frame. It is fit for future use in case background rates are necessary for
policymaking, implementation and surveillance of (public) health interventions, provided
proper and specific (low level) codes exist for disease (sub)groups. This may be particularly
true for the planned efforts to launch recommendations on the benefit of vaccinations for sub-
groups in addition to universal vaccination programmes [52–54]. This holds even truer for
those risk-conditions for which prevalence data are missing, and the size of the targeted sub-
group needs to be estimated.
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